Speakers - 2026

Gynecology Conferences
Magdalena Ufniarz
Medical University of Lublin, Poland
Biography

The presenting author conducts scientific research at the Second Department and Clinic of Gynecology as well as at the Department of Pharmacology of the Medical University of Lublin. His high scientific potential is evidenced by outstanding publication activity. All publications included in his scientific output have appeared in journals ranked in the upper half of the first quartile (Q1) and are characterized by high Impact Factor values. Their scientific merit is further confirmed by a substantial number of citations and a high Hirsch index. Of particular note is the fact that the presenting author’s publications consist of original experimental research. In addition, the presenting author conducts pioneering research aimed at identifying effective treatment strategies for patients with OAB accompanied by depressive symptoms. His studies have demonstrated high efficacy of selected compounds that show real potential for further evaluation in clinical trials. This issue is of particular importance, as no pharmacological agent with proven effectiveness in patients with OAB and comorbid depression is currently known, and no scientific society worldwide has issued therapeutic recommendations for this patient population to date. If the results obtained in the author’s preclinical studies are confirmed in planned clinical trials, they may offer a real opportunity to significantly improve the quality of life of a large population of affected patients.

 

Research interests:

The author’s primary area of scientific interest is the search for novel pharmacological treatment options for overactive bladder syndrome (OAB). This represents a significant clinical and public health problem, affecting approximately 48% of women over the age of 50. Currently available pharmacotherapy (anticholinergics and β3-adrenergic agonists) is associated with limited clinical efficacy and a high incidence of adverse effects, which frequently lead to treatment discontinuation within approximately three months of therapy.